Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
|Articles|January 4, 2022
Pharmacy Clinical Pearl of the Day: Gastrointestinal Stromal Tumors
Author(s)Saro Arakelians, PharmD
Small GISTs may cause no symptoms and may grow so slowly that they have no serious effects.
Advertisement
Clinical Pearl of the Day: Gastrointestinal Stromal Tumors
Gastrointestinal stromal tumors (GISTs) are soft tissue sarcomas located in any part of the digestive system.
Insight:
- Their most common sites are the stomach and small intestine.
- GISTs start in specialized nerve cells located in the walls of the digestive system. These cells are part of the autonomic nervous system.
- A specific change in the DNA of any of these cells, which control digestive processes such as movement of food through the intestines, gives rise to a GIST.
- Small GISTs may cause no symptoms and may grow so slowly that they have no serious effects.
- People with larger GISTs usually seek medical attention when they vomit blood or pass blood in their stool due to rapid bleeding from the tumor.
- Diagnosis starts with upper endoscopy, ultrasound, laboratory tests and biopsy, CT-scan.
- Treatment starts with surgery, targeted drug therapy, with medications such as imatinib (Gleevac) and others.
Sources:
Advertisement
Related to this article
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5